Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Hemostatic drug which has a possible protective effect on the capillary wall along with correction of altered platelet adhesion.
It is used in Menometrorrhagia (Lethaby 2013), prophylaxis on surgical wounds and neonatal intraventricular hemorrhage without a solid evidence of its effictiveness (Hunt 2010, Kuperman 2015).
It is orally, intramuscularly and intravenously administered every 4 - 6 hours for 3 - 4 days.
At latest update relevant published data on excretion into breast milk were not found.
Its high capacity of binding to plasma proteins makes it unlikely a excretion into breast milk.
Due to low frequency and mildness of eventual side effects and/or absence of interference with coagulation mechanisms, seems unlikely this product would affect breastfeeding or the infant.